The Worst News for Celgenehttp://www.fool.com/investing/general/2013/01/07/the-worst-news-for-celgene.aspx Keith Speights
January 7, 2013
Celgene (NASDAQ: CELG) presented today at J.P. Morgan's Annual Healthcare Conference. What was the worst news? The company projects 2013 sales for Revlimid of $4.1 billion to $4.2 billion, while expectations were for $4.3 billion. The worst news was easy to find, though, because it presented about the only negative in a presentation full of good news. Here are the highlights.
More success for apremilast
Earlier successful clinical studies